Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of the International AIDS Society
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir

Authors: S Nozza, L Galli, M Di Pietro, F Mazzotta, F Canducci, M Pogliaghi, S Chiappetta, A Galli, V Rusconi, S Salpietro, G Tambussi, A Lazzarin

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

Current guidelines recommend three drug combinations to treat antiretroviral naïve HIV-infected patients; some data of novel strategies with NRTI-sparing regimen in this setting are now available [1, 2]. The study compares immunovirological efficacy and safety of once daily maraviroc (MVC) plus lopinavir/ritonavir (LPV/r) to tenofovir/emtricitabine (TDF/FTC) plus LPV/r. …
Literature
1.
Mills A, et al: Safety and immunovirological activity of once daily maraviroc in com-bination with ritonavir-boosted atazanavir compared to TDF/FTC QD+ATV/r in treatment-naive patients infected with CCR5 tropic HIV-1 A week 24 planned interim analysis. XVIII IAC. Abs THLBB203
2.
Reynes J, et al: Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with TDF/FTC in treatment-naive HIV-1 infected subjects. XVIII IAC. Abs MOAB0101
Metadata
Title
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
Authors
S Nozza
L Galli
M Di Pietro
F Mazzotta
F Canducci
M Pogliaghi
S Chiappetta
A Galli
V Rusconi
S Salpietro
G Tambussi
A Lazzarin
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P5

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue

Poster presentation

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1

Poster presentation

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy

Poster presentation

Prevalence and factors associated with severe vitamin D deficiency in HIV/hepatitis C co-infected patients

Poster presentation

Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis

Poster presentation

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

Poster presentation

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits